CytoMed Therapeutics (GDTC) Liabilities and Shareholders Equity (2021 - 2025)

CytoMed Therapeutics has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $6.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 18.6% year-over-year to $6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $33.0 million (down 20.6% YoY) and the FY2025 annual result came in at $6.1 million, down 18.91% from the prior year.
• Liabilities and Shareholders Equity declined to $6.2 million in Q4 2025 per GDTC's latest filing, from $8.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $13.9 million in Q2 2023 and troughed at $3.8 million in Q4 2022.
• A 5-year average of $8.0 million and a median of $8.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity jumped 143.24% in 2023, then retreated 23.4% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $4.5 million in 2021, then declined by 15.97% to $3.8 million in 2022, then surged by 143.24% to $9.2 million in 2023, then fell by 17.39% to $7.6 million in 2024, then declined by 18.6% to $6.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.2 million, $8.4 million, and $7.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.